Updated on 3 May 2012
Tibotec is a pharmaceutical company that was established in 1994 by Rudi Pauwels as a drug discovery laboratory and was acquired by Johnson & Johnson in 2002, has been involved in the development of TMC207. This is the first TB compound with a new mechanism of action in 40 years.
Otsuka, Japan, was established in 1964, has been screening TB compounds for about 25 years. The company's OPC-67683 has been in clinical development for about three years.